Results 221 to 230 of about 683,865 (337)

Machine learning-based model for predicting all-cause mortality in severe pneumonia. [PDF]

open access: yesBMJ Open Respir Res
Zhao W   +10 more
europepmc   +1 more source

Development of a Novel Double‐Layered Wound Dressing Composed of Chitosan Film and Tigecycline‐Loaded Electrospun Polycaprolactone Nanofibers

open access: yesJournal of Applied Polymer Science, EarlyView.
The antibacterial double‐layered wound dressing is fabricated using chitosan (CH) film as the contact layer and tigecycline (Tig)‐loaded poly(ε‐caprolactone) (PCL) nanofibers as the top layer. The CH film has a uniform morphology, and the PCL‐Tig nanofibers show a smooth, randomly oriented, and beadless structure.
Ş. Melda Eskitoros‐Togay   +5 more
wiley   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera   +14 more
wiley   +1 more source

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The Phase III MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E Wechsler   +34 more
wiley   +1 more source

MIP-3-Alpha and MIP-3-Beta as Early Predictors of Pneumonia in Polytraumatized Patients. [PDF]

open access: yesLung
Wollner G   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy